From Genomics and Immunogenomics to Treatments of Head and Neck Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 189
Special Issue Editors
Interests: head and neck cancer
Interests: immunotherapy; tumor microenvironment; squamous cell carcinoma; immunosuppression; fibroblast
Special Issue Information
Dear Colleagues,
The world is facing a sharp rise in head and neck cancer (HNC) incidence as predicted by the World Health Organization (WHO), due to the global worsening of air pollution, aging, oncovirus-infection-related endemics, etc. In a few years’ time, by 2030, there will be >1.03 million new cases of HNC per year worldwide. Despite this, we are lacking effective therapies for this aggressive cancer when considering the number of FDA-approved targeted therapies, precision medicines, and immunotherapies that are available today. More translational research efforts and rapid communication of novel research findings that can be potentially translated into future treatments are needed. In this Special Issue entitled “From Genomics and Immunogenomics to Treatments of Head and Neck Cancer”, we encourage the rapid publication of original translational research findings and reviews that will accelerate the translation of HNC genomics, immunogenomics, and multi-omics knowledge into potential therapeutic strategies to transform HNC treatment. These can include articles, either in the form of concept sharing, data-mining, or experimental findings, especially those involving the use of patient-derived models, that address the following areas:
- Novel somatic and germline genomics, immunogenomics, and multi-omics findings, including viral-related events that can be harnessed for treatment development.
- Exceptional responder genomics and omics.
- Novel findings in innate and adaptive immunity in HNC to promote future immunotherapy development.
- From omics data to novel immunotherapy design, including CAR-T, for HNC.
- From omics to novel drug design or treatment strategies for HNC treatment.
We welcome articles and reviews related to various types of HNC, including viral-negative HNC, viral-positive HNC (HPV-associated HNC or EBV-associated nasopharyngeal cancer), and rare cancers of the head and neck.
The overall goal is to provide an updated overview of how to cure HNC based on genomics, immunogenomics, clinical exceptional or durable responder studies, data-mining, and new immunotherapy design and concepts.
We sincerely hope that this Special Issue will encourage the next generation of treatment to be developed, or conceptually designed, to find a cure for this aggressive and devastating cancer.
Dr. Vivian Wai Yan Lui
Dr. Yan Cui
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- genomics
- immunogenomics
- multi-omics
- immunotherapy
- translational research
- preclinical drug development
- clinical trials
